title: Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
authors.affiliation: Clinica di Ematologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Offidani
authors.forename: Pietro
authors.initials: P
authors.lastname: Leoni
authors.forename: Laura
authors.initials: L
authors.lastname: Corvatta
authors.forename: Claudia
authors.initials: C
authors.lastname: Polloni
authors.forename: Silvia
authors.initials: S
authors.lastname: Gentili
authors.forename: Anna Marina
authors.initials: AM
authors.lastname: Liberati
authors.forename: Stefano
authors.initials: S
authors.lastname: Pulini
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Stelvio
authors.initials: S
authors.lastname: Ballanti
authors.forename: Chiara
authors.initials: C
authors.lastname: Nozzoli
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D018572:Disease-Free Survival; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide